Epeius gains two EU nano-based patents for tumor targeting

December 17, 2008: Epeius Biotechnologies Corp., which markets tumor-targeted gene delivery systems, has received two additional European patents for technologies and designs that enable precision gene delivery to primary cancers and metastatic lesions, the San Marino, CA-based company announced in a news release.

The company said that its latest European Union patents follow on the heels of a major clinical patent recently awarded in the United States for targeted in-vivo gene delivery.

The patents provide additional intellectual property protection for the company’s anti-cancer agent Rexin-G. Epeius said Rexin-G is able to reach precise and highly selective diseased tissues based on the company’s recent breakthroughs in tumor-targeting and nanotechnology.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.